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1607-551X/Copyright ª 2014, KaohsiuAbstract The purpose of this study was to evaluate the features of prostate cancer that have
been incidentally detected in radical cystoprostatectomy specimens of bladder cancer pa-
tients. The researchers of the current study retrospectively evaluated the data from 119
men who underwent radical cystoprostatectomy at four referral institutions in Ankara, Turkey.
Of the 21 prostate cancer patients, 17 (81%) were aged 60 years; 10 (47.6%) had clinically sig-
nificant diseases; three had a Gleason score of 6, three had a Gleason score of 7, three had a
Gleason score of 8, one had a positive surgical margin along with extracapsular invasion of the
tumor and a high Gleason score, and three patients had a tumor volume of 0.5 cm3, of which
two also had a high Gleason score. Patients were followed-up for a mean of 29  10.2 months;
the overall survival was 96.6% (n Z 115) during that period. Preoperative digital rectal exam-
ination and prostate-specific antigen values did not differ between the benign and prostate
cancer groups. There was no survival advantage in the insignificant prostate cancer and benign
prostate groups. No additional benefit for predicting prostate cancer was found with digital
rectal examination and prostate-specific antigen tests, although some clinicians advised such.
In patients aged < 60 years, organ-sparing cystectomy seems reasonable. In prostate-sparingave no conflicts of interest to declare.
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372 B.C. O¨zgu¨r et al.surgery, candidates who are aged >60 years, the preoperative work-up may routinely include
prostate biopsy, especially the apex. Preoperative findings of multifocality of bladder cancers
and the presence of carcinoma in situ have the risk of prostatic involvement.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
In men with localized muscle invasive bladder cancer, radical
cystoprostatectomy (RCP) with bilateral pelvic lymphade-
nectomy and different types of urinary diversion remains the
gold standard therapy [1]. During this procedure, whether to
spare the entire prostate or a portion has become controver-
sial in recent years. Some say that sparing the entire prostate
improves both urinary continence and erection, whereas
others say that oncologic outcomes worsen due to the po-
tential risk of not removing the synchronous prostatic
adenocarcinoma [2]. In addition to treating bladder cancer,
the early diagnosis and treatment of lethal prostate cancer
should be the primary goal. Prostate cancer has a wide spec-
trum, andmany prostate cancer patients receive unnecessary
treatment because a number of cases will never become
clinically significant and result in death. By contrast, some
malignanciesmust be treated immediately, as it is well known
from the clinically detected prostate cancers. In this multi-
center study, the researchers reviewed the incidence, histo-
pathological features, and clinical outcomes of patients with
incidental prostate cancer found in RCP specimens. They also
investigated the age of the patients, preoperative rectal ex-
amination findings, and prostate specific antigen (PSA) values
and attempted to determinewhether these parameters could
assist in the prediction and better treatment of significant
prostate cancers. In an effort to improve treatment strategy,
the researchers also examined the survival of patients after
RCP with or without significant prostate cancer.Table 1 The age distribution of patients who underwent
radical cystoprostatectomy in the subgroups with prostate
cancer, with significant prostate cancer and with age- spe-
cific tumor staging according to TNM 2009 classification.
Age distribution, y 40e49 50e59 60e69  70
n (%) 8 (6.7) 47 (39.5) 54 (45.3) 10 (8.4)
Prostate cancer 0 4 13 4
Significant prostate
cancer
0 0 7 3
Stage of the prostate
cancer
T2a (4) T2a (8)
T2b (4)
T3a (1)
T2a (3)
T2b (4)Materials and methods
The data of 119 patients who underwent RCP for bladder
cancer between February 2008 and March 2012 at four
referral institutions in Ankara, Turkey were evaluated. All
patients underwent physical examination that included
digital rectal examination (DRE). Serum PSA values were
noted in 98/119 (82.4%) of patients. In addition to routine
bladder evaluations, the presence of prostatic carcinoma in
the specimens and the variables of the Gleason score,
stage, volume of the prostate cancer, and the surgical
margin status were recorded. The prostatic involvement of
bladder cancer was also studied. Routine pathological ex-
amination was used for specimens. After removing the
prostatic tissue from the bladder and fixation in buffered
formalin for 1 day, prostate specimens were step-sectioned
at 5 mm intervals from the apex to base at all centers. All of
the prostate hematoxylin and eosin-stained slides and pa-
thology reports were reviewed by the experienced genito-
urinary pathologists of the hospitals. The Gleason scores
were evaluated according to the World Health Organizationsystem [3]. The results were compared and the Chi-square
test was used to determine statistical significance. The
volume was determined using the following formula: tumor
area  thickness of the slice (5 mm).Results
The mean age of the patients at RCP was 56.2  8.1 years
(range, 46e74 years; Table 1). The mean ages of the pa-
tients with benign prostate pathology and incidental pros-
tate cancer were 55.1  7.8 years and 60.6  4.7 years,
respectively. Incidental prostate cancer was identified in 21
(17.6%) of the 119 patients. For this study, prostate cancer
was considered to be significant if any of the following were
present: Epstein et al. [4] and Bastian et al. [5] defined
criteria, malignancy, prostate cancer tumor volume
0.5 cm3, Gleason score  6, extraprostatic extension,
seminal vesicle invasion, or a positive surgical margin. Ac-
cording to these criteria, of the 21 prostate cancer cases,
10 (47.6%) had significant disease, and three had a Gleason
score of 6, three had a score of 7, three had a score of 8,
one had positive surgical margin along with extracapsular
invasion of the tumor and a high Gleason score, and three
had a tumor volume of 0.5 cm3, of which two had a high
Gleason score. Of the patients with prostate cancers
identified by DRE, all had negative lymph nodes (Table 2).
Preoperative PSAvalueswere available for 98/119 (82.4%)
patients and were similar in both groups [3.56  1.81 ng/dL
(range, 2.2e4.8 ng/dL) in the benign group and
3.78  1.91 ng/dL (range, 0.97e5.32 ng/dL) in the prostate
cancer group]. The mean PSA of the group with significant
prostate cancer was 3.67  1.03 ng/mL (range,
0.97e5.32 ng/mL). During follow-up, four (3.4%) patients
died from bladder cancer. Overall survival was 96.6% (115/
119) after 29  10.2 months of follow-up. Overall survival
was 100% (10/10) in the significant prostate cancer group
Table 2 The characteristics of patients with clinically
significant prostate cancer in radical cystoprostatectomy
specimens.
Number of patients
Gleason sum 6 9
Tumor volume 0.5 cm3 3
Positive surgical margin 1
Extracapsular invasion 1
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Synchronous bladder and prostate cancers 373during that period. None of the patients had biochemical
recurrence of PSA during follow-up (Table 3). Tumors in the
apex of the prostate were found in 14/21 (66.7%) patients.
Prostatic involvement of the bladder cancer was found in 5/
21 (23.8%) of prostate cancer patients (Table 3). All patients
with prostatic involvement had multifocal tumors (nZ 3) or
unifocal tumors with carcinoma in situ (CIS; nZ 2).
The pathological stages of the bladder tumors with
prostate cancer were as follows: pTa in one patient, pT1in
two patients, pT2a in six patients, pT2b in five patients,
pT3a in one patient, pT3b in one patient, and pT4 in five
patients (because of the prostate invasion according to TNM
2009; Table 4).T
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.Discussion
It was recently shown that both prostate and bladder can-
cers have similar genetic origins, and some suppressor
genes play a critical role in both malignancies. In addition,
prostatic stem cell expression has been shown in bladder
carcinomas, thereby demonstrating the common genetic
origin of those malignancies [6,7]. The increase in these
concomitant tumors may be due to genetic disorders and
should be evaluated in randomized trials.
The frequency of incidentally discovered prostate cancer
in cystoprostatectomy specimens is extremely variable due
to several factors. First, the definition of clinically significant
cancer varies among published reports [8]. In the literature,
the proportion of incidental prostate cancer in RCP speci-
mens varies from 17% to 70% [9,10]. Furthermore, clinically
significant prostate cancer ratios vary from 10% to 75%
[11,12]. The pathological section length may be another
reason, along with the pathologist paying more attention to
the bladder. The wide variability of published data from
different countries may also be due to both genetic and
environmental disorders. Further, there are various expla-
nations for the significance of prostate cancer. The favorable
postoperative continence rates, erection status, and quality
of life scores for prostate-sparing cystectomy in a recent
series, lead to an increasing trend to perform organ-sparing
surgery. This trend has made synchronous prostate cancer
and its significancemore important [12]. Themain goal of the
treatment of bladder cancers with RCP is the preservation of
continence and erection, with excellent oncologic results.
Various techniques that preserve postoperative continence
and erection by leaving the apex of the prostate or the entire
tissue are used, but the potential risk of not removing the
synchronous prostatic adenocarcinoma seems to be a prob-
lem. However, most patients who are RCP candidates with
prostate cancer will not die from prostatic disease. Thewide
Table 4 Stage of bladder cancer in radical cys-
toprostatectomy specimens with prostate cancer according
to TNM 2009 classification.
T stage of
bladder cancer
Number of
patients
Significant
tumor
Insignificant
tumor
pTa 1 0 1
PT1 2 0 2
pT2a 6 3 3
pT2b 5 3 2
pT3a 1 0 1
pT3b 1 1 0
pT4 5 3 2
374 B.C. O¨zgu¨r et al.variability of both the cancer rates and significant diseases
results in confusion as to which patients are suitable for
prostate-sparing surgery. Therefore, in an effort to provide
insight into the issue of variability, the researchers of the
current study attempted to document the results from four
referral hospitals. In the present study, prostate cancer was
detected in 21 (17.6%) of 119 RCP specimens and 17 (81%)
patients were aged >60 years. Additionally, significant dis-
ease was detected in 10/21 (47.6%) patients with amean age
of 65.6  6.4 years. Autopsy studies have shown the actual
rate of prostate cancer ranges from 4% to 46% in men aged
50e60 years [13]. Among the patients between these ages in
this study, prostate cancer was found in 4/47 (8.5%). There
were only four patients aged <60 years, with clinically
insignificant diseasewho remained alive. It can be concluded
that no treatment will be given to any of those patients, so
sparing the prostate due to its significance is reasonable. In
patients aged >60 years, there is a sharp increase in the
detection of prostate cancer. Seventeen patientswere found
at that age group; 10 (58.8%) of them had clinically signifi-
cant disease. In addition, among patients aged >70 years,
three had significant diseases. It can be concluded that in
patients aged<60 years, prostate-sparing surgery may be an
option; however, in patients aged>60 years, prostatectomy
is reasonable during cystectomy. In the literature, the per-
centage of patients aged>60 years with clinically significant
prostate cancer is not more than 20%, and in the current
series it was found in 10/64 (15.6%) patients [14,15]. The
researchers of the current study considered the character-
istics of the tumor, such as Gleason score, and positive
margin. The percentage of clinically significant prostate
cancers would be lower, 3/119 (2.5%) patients, if those with
tumor volumes 0.5 cm3 were taken into account, as is the
practice of some authors. The tumor volume limit is critical
becausewhen the tumor is>0.5 cm3, it is believed that it will
begin to exhibit extra organ disease [16,17]. These per-
centages seem low and encourage some surgeons to leave
the prostate. The researchers wish to highlight the high
percentage [10/21 (47.6%)] of significant cancers. Another
important observation was that almost all (10/11) patients
with significant cancer had organ-confined disease, indi-
cating that they all had a chance to be cured in that stage.
The age specific prostate cancer stages are correlated with
published incident rates of the large series [18].
Although, in the current study, survival seemed to be
dependent on bladder cancer in incidentally detected
prostate cancers in RCP specimens, there are nosurveillance data about the patients with prostate cancers
in which prostate-sparing surgery was performed. There-
fore, removing the prostate is reasonable in patients over
the age of which prostate cancer incidence sharply
increases.
In the literature, there are also controversial findings
about the aggressiveness of incidentally detected prostate
cancer with regard to significant disease, Gleason score,
stage, and positive surgical margin. It is difficult to
explain the reason for those findings, because to our
knowledge there is not a randomized study examining the
incidentally detected and clinically detected cancers with
matched score and stage. Only a small group of patients
has been examined for markers of proliferation activity
and aggressiveness, and it was found that incidentally
detected prostate cancers tend to be less aggressive than
clinically detected cancers [19]. However, conclusions
cannot be made, due to the small sample size. In the
present study, 10/119 (8.4%) patients had significant dis-
ease and their overall survival was 100% (10/10) during the
29  10.2-month follow-up. This may show a less aggres-
sive type of tumor, although it is difficult to generalize.
The other important point was the presence of prostate
cancer in the apex. Leaving the apex to preserve conti-
nence and erection is advocated by many clinicians
[20,21]. However, in the current study, the presence of
prostate cancer in the apical region was observed in 14/21
(66.7%) patients. Therefore, in our opinion, without con-
firming the benign pathology with a biopsy, there is a risk
of leaving the malignancy with the apex of the prostate.
The PSA values for 98 patients were available, whereas
DRE findings were noted for all patients. Preoperative DRE
and serum PSA levels were not indicators for cancer in this
study. In eight patients, PSA levels were >4 ng/mL, trans-
rectal prostate biopsy was not performed due to age and
RCP was the planned surgery. In four of the patients, the
prostate pathology was benign, whereas prostate cancer
was identified in the others. The DRE findings did not
indicate prostate cancer in any patients. These findings
demonstrate no benefit of preoperative PSA screening and
DRE in RCP candidates. There are similar reports confirming
these findings [22]. The present prostate cancer ratios are
parallel to the published series, where prostate specimens
were sliced at 5 mm intervals. A study by Aytac and Vur-
uskan [23] demonstrated that several incidental cancers
may have been missed in the 5 mm interval, and that 3 mm
slices of the prostate will increase the incidental cancer
ratios from 8.75% to 32.8%. Although the sample size was
small, a detailed pathological evaluation of cys-
toprostatectomy specimens with smaller intervals may in-
crease cancer rates. Although it is not probable that the
detected cancers will be significant, there may be an
argument about what the optimal section length for
detecting prostate in RCP specimens should be. Increasing
the number of insignificant prostate cancers will not affect
the treatment and survival.
This study used a retrospective design and a unique
patient population that may not represent characteristics
of other populations. It is well known that there are major
differences in the incidence, metastasis, and mortality
rates of prostate cancers in different races and different
regions [24].
Synchronous bladder and prostate cancers 375Bladder cancer involvement of the prostate was found in
five (4.2%) of the specimens, and it is a contraindication of
prostate-sparing surgery. All of those specimens had CIS or
multifocal tumors of the bladder. In our opinion, under
these conditions, intraoperative frozen biopsy may be a
good option prior to performing surgery. Therefore, we
conclude that prostate cancer incidence in RCP specimens
is highly variable. However, a majority of patients were
aged >60 years. In all specimens from patients aged >70
years, prostate malignancies were identified, and they
were all significant and organ confined. In patients aged
<60 years, the risk of prostate cancer is similar to the au-
topsy series, and therefore it cannot be concluded that the
risk of that cancer increases with bladder cancers. Per-
forming prostate-sparing surgery in patients aged <60 years
seems reasonable, whereas it is not advisable in older pa-
tients because of the risk of synchronous prostate malig-
nancy. By contrast, it can be argued that prostate cancer
patients aged >70 years are not suitable candidates for
prostatectomy. However, according to our data, performing
prostatectomy while performing cystectomy seems
reasonable. Although DRE and PSA tests are advised as a
part of bladder cancer work-up by some clinicians, in this
group, preoperative DRE and PSA values were not helpful
parameters in the differentiation of benign lesions and
cancer [25]. If urinary diversion with prostate-sparing sur-
gery is planned, prostate biopsy compromising the apical
region may be offered in the preoperative work-up. Need-
less to say, PSA follow up is mandatory in incidentally
detected RCP patients, and patients with prostate-sparing
surgery should undergo routine bladder cancer follow-up.
Lastly, the preoperative findings of multifocality of the
bladder cancers and the presence of CIS have the risk of
prostatic involvement, and therefore, prostate-sparing
surgery should be avoided in those patients.References
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